Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Azacitidine Venetoclax and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

This phase II trial investigates how well azacitidine, venetoclax, and trametinib work in treating patients with acute myeloid leukemia or higher-risk myelodysplastic syndrome that has come back (relapsed) or has not responded to treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer …

recurrent acute myeloid leukemia
refractory myelodysplastic syndrome
myelodysplastic syndrome
recurrent chronic myelomonocytic leukemia
HRAS
  • 0 views
  • 19 Feb, 2024
Register of Blood Stem Cell Transplantation

Register of patients with blood stem cell transplantations (autologous, allogen).

cell transplantation
  • 0 views
  • 19 Feb, 2024
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

There is currently lack of collaborative data on the epidemiology, clinicopathologic features and treatment outcome of newly diagnosed and relapsed APL in Asia. In addition, there is lack of data comparing oral- As2O3-based regimens with other treatment approaches, including intravenous As2O3,in the frontline or relapsed setting. With the long-term data …

rara translocation
acute promyelocytic leukemia
acute myeloid leukemia
arsenic
leukemia
  • 0 views
  • 19 Feb, 2024
Role of aGVHD Biomarkers on aGVHD Risks

To establish risk rating criteria of biological protein marker, determine the role and consistency of aGVHD biomarkers in aGVHD diagnosis and aGVHD prognosis, and evaluate the the impact on non-relapse mortality and relapse and disease free survival, the multicenter study on aGVHD biomarkers detection in the patients underwent allogeneic hematopoietic …

hematologic malignancies
allogeneic hematopoietic stem cell transplantation
  • 0 views
  • 19 Feb, 2024